Nektar Therapeutics ( NKTR ) is continuing on with development of rezpegaldesleukin, following successful results in atopic dermatitis and this week's results in alopecia areata. I haven't written about NKTR since November 2024, when IScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/w ...